A Prospective Open‐Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The GastroPASS Study

A Prospective Open‐Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The GastroPASS Study

ABSTRACT Upper gastrointestinal (GI) side effects are a main reason for discontinuing bisphosphonate treatment, an important therapeutic option for osteoporosis patients. Consequently, the development of novel formulations with improved tolerability is warranted. In this multicenter prospective, obs...

Full description

Bibliographic Details
Main Authors: Salvatore Minisola, Antonio P Vargas, Giulia Letizia Mauro, Fernando Bonet Madurga, Giovanni Adami, Dennis M Black, Nawab Qizilbash, Josep Blanch‐Rubió
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:JBMR Plus
Subjects:
ALENDRONATE
EFFERVESCENT
GASTROINTESTINAL ADVERSE EVENTS
OSTEOPOROSIS
POSTMENOPAUSAL WOMEN
Online Access:https://doi.org/10.1002/jbm4.10510

Similar Items

Similar Items